Experience with dupilumab in patients with atopic dermatitis
According to recent data, the key molecules in the pathogenesis of atopic dermatitis are the cytokines IL-4 and IL-13, which initiate and maintain Th2 inflammation. Targeted therapy with dupilumab inhibits the signaling function of these cytokines by binding to the IL-4Rα subunit, which is part of t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Association of Paediatric Allergists and Immunologists of Russia (APAIR)
2023-07-01
|
| Series: | Аллергология и Иммунология в Педиатрии |
| Subjects: | |
| Online Access: | https://adair.elpub.ru/jour/article/view/76 |